1	Joint clinical and molecular subtyping of COPD with									
2	variational autoencoders									
3 4	Enrico Maiorino Robert P. Chase	Margherita De Ma Craig P. Hersh	arzio Zhonghui Scott T. Weiss	i Xu Jeong H. Yun Edwin K. Silverman						
5		Peter J. Castaldi <sup>*</sup>	Kimberly Gla	ass <sup>†</sup> *						
6	Channing Division of Network Medicine									
7	Brigham and Women's Hospital									
8		Harvard M	ledical School							

#### Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a complex, heterogeneous disease. Tradi-10 tional subtyping methods generally focus on either the clinical manifestations or the molecular 11 endotypes of the disease, resulting in classifications that do not fully capture the disease's 12 complexity. Here, we bridge this gap by introducing a subtyping pipeline that integrates clinical 13 and gene expression data with variational autoencoders. We apply this methodology to the 14 COPDGene study, a large study of current and former smoking individuals with and without 15 COPD. Our approach generates a set of vector embeddings, called Personalized Integrated 16 Profiles (PIPs), that recapitulate the joint clinical and molecular state of the subjects in the 17 study. Prediction experiments show that the PIPs have a predictive accuracy comparable to or 18 better than other embedding approaches. Using trajectory learning approaches, we analyze the 19 main trajectories of variation in the PIP space and identify five well-separated subtypes with 20 distinct clinical phenotypes, expression signatures, and disease outcomes. Notably, these subtypes 21 are more robust to data resampling compared to those identified using traditional clustering 22 approaches. Overall, our findings provide new avenues to establish fine-grained associations 23 between the clinical characteristics, molecular processes, and disease outcomes of COPD. 24

# <sup>25</sup> 1 Introduction

9

<sup>26</sup> Chronic Obstructive Pulmonary Disease (COPD) is a complex chronic respiratory disease that is
<sup>27</sup> among the leading causes of death worldwide [1]. The disease manifests as a spectrum of conditions,
<sup>28</sup> including persistent airflow obstruction, lung inflammation, chronic bronchitis, and emphysema.
<sup>29</sup> COPD susceptibility has been attributed to a combination of physical, environmental, and genetic
<sup>30</sup> factors, resulting in significant phenotypic variation across individuals.

This heterogeneity has prompted substantial research efforts aimed at dissecting the various manifestations of the disease, to understand their etiological origins, and to predict their outcomes [2]. A practical goal of these studies has been to delineate distinct COPD subtypes by employing advanced clustering and machine learning techniques trained with large datasets of clinical and genomic data extracted from human cohort studies [3, 4].

Current COPD subtyping approaches can be divided into those that characterize the observable phenotypes of the disease (clinical subtyping), and those that focus on disentangling the disease processes, often referred to as "endotypes", underlying various COPD manifestations (molecular

<sup>\*</sup>These authors contributed equally as co-last authors

<sup>&</sup>lt;sup>†</sup>Corresponding author. Email: kimberly.glass@channing.harvard.edu

subtyping) [5]. Applications of the former type leverage clinical data including demographics, disease 39 symptoms, spirometry measurements, or chest imaging [6, 7, 8, 9], whereas applications of the latter 40 type leverage measurements from various omics assays (transcriptomics, proteomics, epigenomics, 41 etc.) [10, 11, 5, 12]. Although both approaches offer valuable insights into different aspects of the 42 disease, subtype classifications from these applications are exclusively defined within either the clinical 43 or molecular domain, with the analysis in the other domain performed primarily for validation or 44 post-hoc examination [13, 6, 8, 11, 5]. Consequently, these domain-specific classifications cannot 45 capture disease mechanisms arising from the interaction between molecular processes and clinical or 46 lifestyle factors [14, 15, 16, 17], potentially leading to inconsistent subtypes that are not reproducible 47

across different patient cohorts [18].

Multi-omics data integration is a widely researched subject [19, 20, 21], and multiple methods 49 have been developed for this purpose, such as MOFA [22], iCluster [23] and SNF [24]. In contrast. 50 the simultaneous integration of both clinical and omics data for disease subtyping has received 51 comparatively less attention, with its applications in COPD being confined to specific domains [25]. 52 One of the challenges in integrating omics and non-omics data is their inherent complexity. Data 53 heterogeneity and bias, already present in multi-omics studies [26], are exacerbated when including 54 clinical data, which is typically composed of complex data structures with heterogeneous correlation 55 patterns and significant variation in terms of scales, sparsity, and noise [27]. To alleviate these 56 issues and to account for potential nonlinear interactions between variables from different domains, 57 specialized integrative methodologies based on autoencoder neural networks have been proposed in 58 several disease contexts, including COPD [10] and cancer [28, 29, 30, 31]. However, a comprehensive 59 subtyping analysis that integrates both the clinical and molecular domains of COPD has not been 60 performed. 61

In this work, we propose a joint subtyping approach to integrate clinical and gene expression 62 data extracted from the COPDGene Study [32] (see Fig. 1 (a)), a large study of current and 63 former smokers with and without COPD. Building on recent developments in multi-modal learning 64 [33, 34], we developed an integrative method based on variational autoencoders (VAEs). A VAE is 65 an unsupervised neural network architecture designed to compress the input data and generate a 66 set of compact encodings [35]. We trained the VAE with clinical, imaging, and transcriptomic data 67 from COPDGene, generating a set of personalized integrated profiles (PIPs) that encode the joint 68 clinical and molecular configuration of every individual in the population. By performing multiple 69 outcome prediction experiments, we demonstrate that the generated PIPs are highly informative of 70 the individual's disease state and enable accurate prediction of future disease outcomes. Next, we map 71 the continuous trajectories in the VAE space using a recently proposed trajectory learning technique 72 [36]. Through this approach, we identify several well-separated disease states, each exhibiting distinct 73 clinical and molecular characteristics (joint subtypes). Finally, we show that these joint subtypes are 74 characterized by different disease progression patterns and mortality and that they are robust to 75 resampling noise. 76

# 77 2 Results

COPDGene is an ongoing longitudinal multi-center study of current or ex-smoking individuals with 78 and without COPD who have undergone extensive clinical, physiological, and radiological profiling 79 at three time points across 10 years (Phase 1, 2, 3, see Fig. 1 (b)). Additionally, periodic long-term 80 follow-up (LFU) surveys have been conducted every 6 months throughout the duration of the study. 81 10,198 individuals were enrolled at baseline. In this work we considered all of the subjects with clinical 82 and blood gene expression data in Phase 2 (five-year follow-up) of the study that were available at the 83 time of analysis (3,628 subjects, see Fig. 1 (c)). Clinical data includes demographics, lifestyle factors 84 (e.g., smoking habits), spirometry measurements, medical and medication history, chest CT imaging 85 measures, respiratory symptoms, and complete blood counts (CBC). Gene expression data consists of 86 whole blood RNA-seq profiling. Both of these data modalities have been used extensively for COPD 87 subtyping [6, 7, 8, 9, 11, 5], and they are among the most widely-used read-outs of the phenotypic 88



Figure 1: Overall organization of this work. (a) Joint subtyping aims at generating subtypes based on both clinical and molecular features. (b) COPDGene study design. Data from study stages preceding Phase 2 (gray) are not used in this work. On the right of the timeline are described the types of data collected at each study stage and considered in this study. Phase 2 and Phase 3 of the study are spaced approximately 5 years apart. LFU (Long-term Follow-Up) data consists of survey assessments conducted approximately every 6 months in between study phases. (c) Starting from the COPDGene population, an array of clinical and molecular features is extracted and used for training the VAE. The autoencoder produces a set of personalized integrated profiles (PIPs), one per individual in the population. (d) Architecture of the VAE. Expression and clinical features are concatenated with conditional variables (age, sex, race) and processed separately in two encoder subnetworks. The two encodings are subsequently merged in a shared latent representation (PIP). Next, the latent representation is concatenated to the conditional variables and processed with two separate decoder subnetworks to reconstruct the original data.

and molecular manifestations of COPD. To merge these two data types in a single representation of
 disease state, we designed a data integration scheme based on Variational Autoencoders (VAEs).

VAEs are probabilistic unsupervised neural network models designed to compress the input to

92 generate low dimensional representations [37]. VAEs exploit statistical dependencies between input

variables to construct a small set of variables (latent code) that preserve most of the input information.

<sup>94</sup> In contrast to linear techniques such as Principal Component Analysis (PCA), VAEs can capture

nonlinear relationships between variables [38]. Drawing inspiration from other recently proposed

architectures for multi-modal data integration [29, 30], we modified the standard VAE architecture so

as to process and merge two data types (see Fig. 1 (d) and Methods). Our model implicitly performs

a 2-step dimensionality reduction. The hidden layers in the encoder network (H1/2-expr, H1/2-clin in 98 Fig. 1 (d)) process the two data types separately to obtain a data-type-specific representation of the 99 input features. These representations are then coupled to generate a joint latent representation that 100 encodes both the clinical and molecular information, which we refer to as "Personalized Integrated 101 Profile" (PIP). Given the probabilistic nature of the VAE model, it is possible to correct for potential 102 confounding factors by including them as a set of conditional variables [39]. These conditional 103 variables have a similar role as regression covariates in linear regression modeling. Therefore, we set 104 the age, sex, and race of each individual as conditional variables in both data modalities to regress 105 out their effect on the learned representation. 106

The data processing and integration pipeline consists of several steps (see Methods for further 107 details). In brief, we designed two separate processing pipelines for the two data types, consisting of 108 feature selection and normalization operations. The resulting set of features selected for training 109 the VAE is summarized in Supplementary Table 1. Next, we split the dataset into training and 110 validation sets (80%/20%). We trained the VAE on the training set, and used the validation set for 111 hyperparameter selection. We performed hyperparameter optimization to determine the optimal 112 network depth, layer size, learning rate, and number of components of PIP vectors (latent components). 113 Our primary objective was to select parameter configurations that resulted in high reconstruction 114 accuracy of the validation set data, with a preference for configurations with fewer latent components. 115 We determined that the optimal number of components in terms of reconstruction quality and latent 116 vector size is 30. After training the network with the optimal parameters, we then used the Encoder 117 subnetwork to generate the PIPs of the full dataset. The generated PIPs are the starting point of 118 the subsequent analysis to identify joint subtypes of COPD. 119

### <sup>120</sup> 2.1 Predicting future disease states with Personalized Integrated Profiles

The PIPs generated by the VAE contain information on both the expression and clinical features of 121 a subject. To test the VAE's performance in compressing and integrating different data modalities 122 without sacrificing important information, we set up a prediction task of several prospective COPD 123 outcomes. The COPD outcomes included all-cause mortality at 3 and 5 years after the Phase 2 and 124 other clinical measurements collected in Phase 3 (P3) of the study, approximately five years after 125 Phase 2 (P2) visits (see Methods for further details). These variables are extracted exclusively from 126 data collected after Phase 2 of the study and thus were not used to train the VAE. We perform the 127 classification using a Random Forest classifier, and define the PIP vectors as input variables and the 128 Phase 3 outcomes as target variables (see Methods for details). For comparison, we evaluated the 129 performance of the same classifier trained using other types of embedding as input: PCA of clinical 130 variables (Clin PCA); PCA of expression variables (Expr PCA); PCA of concatenated expression 131 and clinical variables (Expr + Clin PCA); Canonical Correlation Analysis (CCA) scores of the 132 expression (Expr CCA) and clinical variables (Clin CCA); and factors calculated by applying the 133 integrative method Multi Omics Factor Analysis (MOFA) [22] to expression and clinical variables. 134 The performance metrics for the prediction, presented in Table 1, were derived from a 5-fold stratified 135 validation repeated 3 times and then averaged (additional measures are reported in Supplementary 136 Table 2). The VAE-based PIPs consistently achieve either the highest or second-highest scores across 137 most prediction tasks. In the cases where the PIPs do not outperform other embeddings, no other 138 alternative embedding scheme emerges as a clear leader in performance. This finding indicates that 139

despite encoding a broader range of information compared to domain-specific alternatives (e.g. Clin
PCA), the PIPs retain substantial information about an individual's disease state and its likely
outcomes.

				F1-score			
	Clin PCA	Expr PCA	$_{\rm Expr+Clin\ PCA}$	Expr CCA	Clin CCA	MOFA	VAE
$\Delta$ FEV <sub>1</sub> % of pred.	0.75(0.03)	0.74(0.04)	0.73(0.03)	0.75 (0.04) [n.s.]	0.74(0.04)	0.74(0.04)	0.73(0.04)
Inc. chronic bronchitis	0.02(0.04)	$0.01 \ (0.03)$	0.04(0.06)	0.03 (0.05)	0.04(0.05)	0.07(0.07)	$0.12 \ (0.08) \ ^{**}$
Exacerbations (P3)	0.37(0.09)	0.09(0.06)	0.35(0.06)	0.23(0.07)	0.23(0.08)	0.25(0.09)	0.41 (0.08) *
$\Delta$ Exac. Freq. (P3>P2)	0.10(0.08)	0.04(0.05)	0.14(0.07)	0.12(0.07)	0.12(0.08)	0.09(0.06)	0.20 (0.11) **
Sev. Exacerbations (P3)	0.11(0.07)	0.04(0.04)	0.11(0.08)	0.04 (0.05)	0.03(0.04)	0.06(0.06)	$0.15 \ (0.08) \ ^{*}$
$\Delta$ Sev. Exacerbations (P3>P2)	0.08(0.06)	0.03(0.05)	0.06(0.08)	0.00(0.02)	0.01 (0.03)	0.04(0.06)	0.11 (0.07) [n.s.]
$\Delta$ MMRC (P3>P2)	$0.\overline{29} (0.05) *$	0.18(0.05)	0.18(0.05)	0.24(0.04)	0.22(0.05)	0.20(0.05)	0.26(0.04)
$\Delta$ SF-36 (P3 <p2)< td=""><td>0.58(0.03)</td><td>0.59(0.03)</td><td>0.60(0.03)</td><td>0.60(0.02)</td><td><math>0.61 \ (0.02) \ ^{*}</math></td><td>0.58(0.03)</td><td><math>\overline{0.59\ (0.03)}</math></td></p2)<>	0.58(0.03)	0.59(0.03)	0.60(0.03)	0.60(0.02)	$0.61 \ (0.02) \ ^{*}$	0.58(0.03)	$\overline{0.59\ (0.03)}$
Mortality (3yr)	0.08(0.04)	0.12(0.05)	0.11(0.05)	$\overline{0.13 (0.06)}$	0.13(0.06)	0.10(0.03)	$0.17 \ (0.05) \ ^{*}$
Mortality (5yr)	0.23(0.05)	0.19(0.04)	0.23(0.03)	0.25 (0.05)	$\overline{0.25(0.04)}$	0.20(0.04)	0.30 (0.06) **

Table 1: Prediction performance (F1-score) of COPD outcomes. Best performances and second-best are respectively displayed in bold or underlined. Abbreviations:  $\Delta$  = change from P2 to P3, P2 = phase 2 of COPDGene, P3 = phase 3 of COPDGene, (P3>P2) = value at P3 larger than value at P2, pred.=predicted, inc. chronic bronchitis = chronic bronchitis not present at P2 but present at P3, exac. freq.=exacerbations frequency

### <sup>143</sup> 2.2 Summarizing COPD heterogeneity with principal graphs

The PIPs generated by the VAE are vectors distributed in a 30-dimensional space of variables that 144 implicitly describe the joint molecular and clinical characterization of every individual analyzed in our 145 COPDGene dataset. The geometry of the distribution of these generated vectors in the VAE space is 146 therefore informative of the patterns of variability of COPD features in the population, including the 147 presence, or lack thereof, of separate clusters. Growing evidence suggests that COPD manifestations 148 may form a continuous spectrum of disease states[3]. Under such circumstances, characterizations 149 based on discrete clusters may impose arbitrary boundaries within subpopulations that may impact 150 the robustness of the subtypes. To overcome this issue, we analyzed the trajectories of continuous 151 variation of COPD in the VAE space. We used the elPiGraph method [36], an algorithm to fit 152 a branching network structure to a set of points in a multidimensional space. ElPiGraph and its 153 adaptations have been previously used to identify trajectories in several contexts, including the 154 clinical domain of COPD [40] and the molecular domain of cancer [41]. In this study, we extend its 155 application to the joint domain of clinical and molecular features of COPD. 156

In brief, elPiGraph produces a tree-like network, called *principal graph*, that is embedded in the VAE space. elPiGraph optimizes the coordinates of the nodes of the principal graph to minimize their distance from the data points. In this way, the principal graph traverses the main axes of variation of the data points, approximating their intrinsic geometry. This procedure results in a mapping between each data point and its corresponding projection onto the tree branches, providing information on their relative positioning along the main axes of variation.

We applied elPiGraph to construct the principal graph of the population and associated each 163 subject to their closest network branch in the space. The fitted principal graph is composed of 5 164 terminal branches, i.e., tree branches connected to the remaining graph only through one endpoint, 165 and 2 non-terminal branches, i.e., those connected at both their endpoints (see Fig. 2 (a)). Since 166 we were interested in identifying subtypes with distinct disease features and minimal overlap, we 167 restricted the analysis exclusively to the individuals within the terminal branches. Further, to 168 maximize the separation between different branches, we selected only the 50% of data points that lie 169 on the most extreme ends of each branch (see Methods and Figs. 2 (b) and Supplementary Figs. 1 170 (a-f)). Overall, 1,552 individuals were selected as members of any of the 5 branches. 171



Figure 2: Features of the principal graph constructed from the COPDGene PIPs. (a) Principal graph layout. Large black dots and edges represent the fitted graph structure. Smaller dots represent individuals in the population, where the position is determined according to their proximity to the graph nodes. Points highlighted in orange are members of the terminal branches, while gray points are in non-terminal branches. (b) Colored dots represent the individuals selected as members of each branch after thresholding. Gray dots are individuals that are not assigned to any branch. (c-f) Distribution of selected features in each branch (top) and across the principal graph (bottom). All the graph layouts are generated with the Kamada-Kawai algorithm. Abbreviations: Pred.=predicted, Exac.=Exacerbations

## <sup>172</sup> 2.3 The joint subtypes have distinct clinical characteristics

Of the 5 terminal branches, 3 are composed mainly of individuals with GOLD stage 2-4 corresponding to moderate-to-severe COPD (bottom left branches in Fig. 2 (b)), whereas 2 branches (referred to as NORM1 and NORM2) are composed mainly of individuals with preserved lung function or mild COPD, i.e. GOLD stage equal to 0-1 (top right branches in Fig. 2 (b)). The branches are characterized by different phenotypic profiles (see Supplementary Table 3).

The NORM1 and NORM2 branches differ primarily in mean age (NORM1:  $67\pm8.2$  yrs, NORM2:  $61\pm8.5$  yrs), current smoking status (NORM1: 18%, NORM2: 44%), and blood cell type composition (predominantly neutrophilic in NORM1 and lymphocytic in NORM2).

The SEV branch consists of older individuals  $(68.7\pm8.3 \text{ yrs})$  with the most severe disease manifestations - low lung function (52% of predicted FEV<sub>1</sub>), frequent and severe exacerbations,

and high prevalence of chronic bronchitis (Figs. 2 (c-f)). These individuals also have a marked
degree of emphysema, air trapping, and thickened airway walls. Consistent with the severity of
their condition, self-reported metrics such as the mMRC dyspnoea scale and SGRQ scores indicate a
severely compromised quality of life. Despite the high average number of pack years, the SEV branch
is characterized by the smallest proportion of current smokers (31%) compared to other branches.
This trend likely reflects the tendency of subjects with severe COPD to stop smoking.

The MOD branch consists of younger individuals  $(59.7\pm6.3 \text{ vrs})$  with moderately impaired lung 189 function and low percentage of emphysema and moderate airway wall thickening. However, compared 190 to other branches (excluding SEV), MOD subjects are affected by a higher average frequency of 191 exacerbations, and the severity of their respiratory symptoms is similar to those observed in the 192 SEV branch, with an average mMRC score of  $2.4\pm1.3$  compared to  $2.7\pm1.2$  in the SEV branch and 193 an SGRQ total score of  $46.2 \pm 19.7$  versus  $48.7 \pm 18.6$ . In line with previous studies [42], we defined 194 frequent exacerbators as those individuals who experience two or more exacerbations in a year. The 195 MOD branch has the second-largest proportion of frequent exacerbators (17%) after SEV (25%), 196 and this subgroup has a substantial proportion of subjects in GOLD spirometric stage 2 or PRISm 197 (preserved ratio impaired spirometry) group [43] (Supplementary Figure 2). Subjects in the MOD 198 branch tend to have a phenotype that has been associated previously with airway-predominant 199 COPD, with the highest average BMI and lowest amount of emphysema of all branches, as well as 200 thick airways. 201

Individuals in the SYMPT branch are similar in most aspects to NORM1 and NORM2 branches
 (mild airway obstruction, low percent emphysema, infrequent exacerbations), yet this group has a
 larger proportion of current smokers and airway inflammation symptoms, such as cough, phlegm,
 and chronic bronchitis.

We examined the relation between the five branches and other previously proposed COPD 206 subtypes. As emphysema is a common feature of COPD, recent works have distinguished classified 207 phenotypes as emphysema-predominant (EPD, defined in individuals with GOLD>1 as CT-quantified 208 densitometric emphysema  $\geq 10\%$  at -950 Hounsfield units), non-emphysema-predominant (NEPD, 209 CT emph. <5%) and intermediate emphysema (IE, CT emph. between 5% and 10%) [44]. The 210 breakdown of each branch into separate classes shows that the SEV branch contains the largest fraction 211 of EPD individuals (46%, see Supplementary Figure 3), a smaller fraction of NEPD individuals 212 (23%), and negligible components of other states. Comparatively, the MOD branch is composed 213 of a substantial proportion of NEPD individuals (22% overall, 62% within GOLD>1 stages) and 214 only 8% of EPD phenotypes. Furthermore, MOD has the largest proportion (20%) of individuals 215 in preserved  $FEV_1/FVC$  ratio and impaired spirometry (PRISm). The remaining three branches 216 (SYMPT, NORM1, NORM2) are composed mainly of individuals without significant COPD features 217 and therefore contain negligible proportions of subjects with GOLD stage > 2. 218

## <sup>219</sup> 2.4 The joint subtypes have distinct transcriptomic signatures and path-<sup>220</sup> way activations

We analyzed the transcriptomic differences between the SEV, MOD, and SYMPT branches using the 221 combined NORM1 and NORM2 branches as the reference group (see Methods). Through differential 222 expression (DE) analysis, we identified a set of DE genes for each contrast (see Supplementary Table 223 4). For each set, we performed gene set enrichment analysis (GSEA) [45] using the 50 hallmark 224 pathways of MSigDB [46] to find the over- or under-expressed biological pathways in each branch. The 225 results are shown in Fig. 3, where it is evident that the SEV and MOD groups differ markedly in the 226 expression of multiple biological pathways. Among the most significant pathways (FDR p-adj.<0.05), 227 Interferon Alpha (IFN- $\alpha$ ) Response is highly over-expressed in the SEV and SYMPT branches and 228 under-expressed in the MOD branch. The Oxidative Phosphorylation pathway is upregulated in both the SEV and MOD branches, while the Reactive Oxygen Species (ROS) pathway is upregulated only 230 in the SEV branch and downregulated in the MOD branch. The majority of GSEA leading genes 231 in the MOD branch are antioxidant agents. Among these, differential expression analysis reveals 232



Figure 3: Gene set enrichment analysis of the differentially expressed genes between each branch and the NORM1 and NORM2 branches. Opaque points represent pathways that are significant (FDR p.adj.<0.05), while transparent points are non-significant. NES=normalized enrichment score.

downregulation of the antioxidant enzymes GPX3, G6PD, GSR, and TXNRD2 [47, 48].

## <sup>234</sup> 2.5 The joint subtypes are associated to distinct disease outcomes and <sup>235</sup> risks

Next, we examined the associations between the joint subtypes and a set of COPD-related clinical 236 outcomes. We collected data from the LFU dataset, in which COPDGene participants self-reported 237 health updates via a survey every 6 months during the whole duration of the study (see Methods). 238 Given that respiratory exacerbations are associated with COPD progression, we examined their 230 temporal patterns among subjects from various branches. The temporal exacerbation patterns of the 240 branches closely mirror the cross-sectional behavior observed during Phase 2 (Fig. 4 (a)), with the 241 individuals in the SEV and MOD branches experiencing a higher rate of exacerbations throughout 242 the entire time period. Interestingly, individuals who reported zero exacerbations in Phase 2, yet were 243 classified in the SEV (163) and MOD (124) branches, demonstrated a significantly higher likelihood 244 of experiencing one or more exacerbation events following Phase 2 - 42% and 50\%, respectively – 245 compared to the NORM1 and NORM2 branches (8%) and the SYMPT branch (16%). This finding 246 suggests that branch membership can provide insights into the potential for future exacerbations, 247 even when the present data does not explicitly indicate it. Moreover, to address potential confounding 248



Figure 4: Prospective analysis of the branches. (a) Temporal trends of exacerbations among COPDGene subjects, categorized by their respective branches. Each row represents a subject, and different colored areas within these rows denote the number of exacerbations experienced by that subject during a 6-month timeframe. The color intensity corresponds to the number of exacerbations, with darker or larger areas indicating a higher number of exacerbations. (b) Incidence rate ratio (IRR) of exacerbations between each branch and the reference group, NORM2. (c) Distribution of FEV<sub>1</sub> % of predicted levels categorized by branch (color), and by study phase (light=P2, dark=P3). (d) Distribution of relative changes in FEV<sub>1</sub> % of predicted categorized by branch. (e) Kaplan Meier curves of mortality, categorized by branch. (f) Hazard ratio (HR) of mortality between each branch and the reference group, NORM2.

factors, we used a Poisson regression model to analyze the incidence of exacerbations in the LFU data, adjusting for the age, sex, and race of each participant (see Methods). The calculated incidence rate ratios of each branch, using NORM2 as the reference, demonstrate that these insights are consistent

even when adjusting for demographic differences between the subpopulations (Fig 4 (b)).

Next, we assessed the change in FEV1 % of predicted values over the five years between the Phase and Phase 3 visits (Figs 4 (c) and (d)). The SEV and MOD branches showed the largest decline in FEV<sub>1</sub> % of predicted, whereas the other three branches had a smaller decrease within the selected time frame. Finally, we estimated the mortality risk associated with each branch(see Fig. 4 (e) and (f) and Methods). The SEV and MOD branches demonstrate respectively a 5-fold and 2-fold average hazard ratio compared to the NORM2 branch, while the other branches do not exhibit increased risk.

### 259 2.6 The joint subtypes are robust to retraining and data resampling

To quantify the stability of the VAE space with respect to resampling of the training data, we 260 performed two different robustness tests. In the first test, we evaluated the stability of the PIPs 261 to random re-samplings of the training data. We retrained the VAE 100 times with different 262 train/test splits (80%/20%), selected randomly) and generated 100 new sets of embeddings of the 263 whole population ("resampled" embeddings). Each of these sets of embeddings correspond to the 264 PIPs that would be generated by the VAE under scenarios where different subsets of the data were to 265 be held out. In the ideal case, the resampled embeddings should provide similar information as the 266 original embeddings, indicating that the identified patterns of variability are general and robust to 267 noise. Therefore, we measured the overall similarity between the original and each resampled set of 268 embeddings using the distance correlation measure (dCorr) [49]. dCorr is an extension of the Pearson 269 correlation to multivariate settings and it ranges between 0, indicating statistical independence, and 270 1, suggesting a linear relationship between the two variables (see Methods for further details). We 271 measured a distribution of correlation values of  $0.900 \pm 0.006$ , indicating a strong similarity between 272 the generated profiles. 273

As a second test, we tested the stability of the branch assignments to random resamplings of the 274 training data. For each of the resampled embeddings described above, we constructed a principal 275 graph (using the same settings) and assigned each point to a branch of the new graph (resampled 276 branches). To measure the robustness of each of the original branches (SEV, MOD, SYMPT, NORM1, 277 and NORM2), we defined the cluster purity measure as the proportion of subjects of each branch that 278 were classified within the same branch in a resampled graph (see Methods). A high cluster purity 279 indicates that individuals within the same cluster tend to be classified in the same cluster also in the 280 resampled configurations. For each branch, we evaluated its purity against each resampled branch 281 classification. In this way we obtained a set of 100 purity values per branch. For comparison, we 282 repeated a similar operation by running the k-means algorithm on both the original VAE embeddings 283 and each resampled embedding. For each embedding, we set a number of clusters equal to the number 284 of branches identified within that embedding. Finally, we evaluated the purity values of each of the 285 clusters retrieved in the original VAE embedding. Since the selection of non-terminal branches in 286 the trajectory analysis has no equivalent operation in the clustering case, for the comparison we 287 selected the 5 clusters with the highest median purity values. Additionally, to emulate the selection 288 of the 50% highest confidence points along the trajectories, for each cluster we selected the 50% data points that are closest to the cluster centroid ('core set' of the cluster). The identified branches yield 290 high purity values, approximately 90% for all branches (Supplementary Figure 1 (g), red boxes), 29 outperforming both the standard k-means clusters (light blue boxes) and their core sets (dark blue 292 boxes). This finding indicates that the branches are more robust to random resampling compared to 293 the k-means clusters, suggesting that the principal graph description better reflects the continuous 294 nature of the underlying data distribution. 295

# <sup>296</sup> 3 Discussion

In this study, we proposed a novel approach to COPD subtyping, bridging the often-separate realms
of clinical phenotyping and omics-driven profiling. Our main contributions are: (1) we showed that
by integrating clinical and molecular data through variational autoencoders we retain domain-specific
information while simultaneously capturing variability across multiple domains; (2) we showed that

trajectory analysis in the joint clinical and molecular space of COPD features identifies more robust subgroups compared to standard clustering approaches; (3) we identified 5 joint subtypes with distinctive clinical and transcriptomic features and disease outcomes.

The rationale of this work is that when clinical features aren't explicitly included in the discovery phase of subtyping, it can be challenging to ensure that the derived molecular subtypes hold clinical 305 relevance [10]. Adding to previous work in multi-omic integration [19, 50], we designed a variational 306 autoencoder architecture to integrate blood gene expression and clinical variables in COPD. While 307 previous studies have focused on finding associations between clinical and molecular variables in specific 308 contexts, such as CT imaging data [51], our integrative methodology describes this connection at a 309 larger scale. Instead of focusing on a specific feature domain, we generated a comprehensive description 310 of the COPD heterogeneity across multiple domains, including transcriptomics, demographics, lung 311 function, lifestyle, CT measures, medical history, comorbidities, and symptoms. 312

Linear multi-omics integration methods, such as MOFA [22], assume a linear relationship among the features. In contrast, variational autoencoders offer flexibility in capturing complex, non linear interactions between features coming from different domains. The VAE architecture at the core of our methodology is designed to perform an implicit 2-step integration process. The first step consists in integrating features within the same domain (clinical or molecular). Then, the domain-specific higher-level features are subsequently integrated together to encode the Personalized Integrated Profile of a subject.

Several recent works have suggested that COPD manifestations are usually distributed as a 320 continuum rather than discrete subgroups [18, 3], possibly stemming from the superposition of 321 multiple endotypes [52]. In the absence of clearly-separated subpopulations, subjects with intermediate 322 or hybrid COPD conditions are only loosely associated to their subtypes, and even slight noise 323 perturbations can cause these subject to "switch" to adjacent groups. To address this issue, we used 324 the elPiGraph trajectory learning algorithm [36] to map the main trajectories of the VAE latent space. 325 Trajectory analysis yields an explicit linear ordering of individuals along each branch, generalizing 326 the previously proposed concepts of "treatable traits" [52] and "disease axes" [53, 3]. We selected 327 subjects with more extreme conditions to define subgroups, reducing the susceptibility to group 328 switching. This approach improves the subtypes' robustness compared to standard clustering-based 329 classifications, since in the latter the points with the highest confidence are those nearest to the 330 centroid, and therefore reflect more average, rather than extreme, features. 331

Our analysis identified five joint subtypes with distinct phenotypic characteristics, severity, disease 332 outcomes, and transcriptomics signatures. Three of these five subtypes present multiple COPD-like 333 features. The subtype with the most severe COPD manifestations, SEV, includes the largest fraction of individuals with emphysema. The SEV group has the largest overlap with the established definition 335 of emphysema-predominant phenotypes (>10% CT-quantified emphysema), a subtype previously 336 associated to larger annual  $FEV_1$  loss and higher risk of mortality [44]. Conversely, MOD individuals 337 with moderate-to-severe COPD ( $GOLD \ge 2$ ) have large overlap with the non-emphysema-predominant 338 subtype of COPD (<5% CT-quantified emphysema). Individuals within the MOD subtype, despite 339 their relatively younger average age and lower disease severity, experience frequent exacerbations 340 and lose lung function at a comparable rate to the SEV group, consistent with prior observations 341 linking exacerbations to loss of lung function [54, 55, 56, 57]. Notably, the fraction of frequent 342 exacerbators in MOD (>2 exac. per year, as defined in [42]) is composed predominantly (83%) of 343 mildly obstructed individuals ( $GOLD \leq 2$  or PRISm). The association between frequent exacerbations 344 and milder airflow obstruction in certain COPD subgroups has been demonstrated previously, both 345 within COPDGene (Phase 1) [54] and within the ECLIPSE study [42]. Individuals in the MOD 346 subtype may be representative of earlier-stage COPD mechanisms where frequent exacerbations 347 precede the development of severe airflow obstruction. An alternative possibility is that they represent 348 a distinct trajectory of COPD characterized by airway inflammation and frequent exacerbations 3/10 without emphysematous lung destruction. 350

Subjects in the SYMPT subtype are mostly current smokers ( $\sim$ 70%) with only slight spirometric abnormalities and relatively favorable disease progression, yet they suffer from multiple respiratory

symptoms, including chronic bronchitis, coughing and wheezing. SYMPT individuals are reminiscent of the previously investigated subtype of symptomatic smokers with preserved lung function (FEV<sub>1</sub>:FVC $\geq$ 0.70) [58, 59]. In agreement with the findings in [58], using LFU measurements we found that subjects within this subtype experience higher exacerbation frequency compared to the NORM2 baseline. However, in our prospective analysis we did not observe a substantial difference in loss of lung function between the SYMPT and the NORM1 and NORM2 subtypes.

Besides recapitulating previously observed patterns of phenotypic variation, the joint subtypes 359 display marked transcriptomic differences. We measured a distinct pattern where multiple biological 360 pathways exhibit an opposite directionality of activation between the SEV and MOD branches. 361 Immune pathways, which are among the top enriched processes, have been consistently associated to 362 COPD [11, 60, 61]. Among the most significant differences, we found several pathways related to 363 immune response and regulation, including Interferon Alpha response, IL6/JAK/STAT3 Signaling 364 and TNF- $\alpha$  Signaling via NF- $\kappa$ B. COPD patients who experience frequent exacerbations have been 365 reported to exhibit reduced IFN- $\alpha$  levels in response to viral infection compared to individuals 366 with lower exacerbation rates [62]. As such, downregulation of the IFN- $\alpha$  in the MOD branch 367 might indicate compromised antiviral immunity, potentially leading to a higher susceptibility to 368 exacerbations. ROS overproduction is known to suppress the activity of these enzymes [63, 64, 65, 66], 369 and prolonged depletion of antioxidant capacity has been observed several days after the onset of 370 exacerbation in COPD patients. Furthermore, previous reports have supported the role of the 371 IL6/JAK/STAT3 signaling pathway in pulmonary inflammation and COPD severity [67, 68]. 372

One limitation of this study is that we rely exclusively on expression data in blood for inferring 373 the molecular processes associated to each subtype. The integration of diverse omics types and 374 tissues [19], especially from the lung and airways, will be crucial for delineating more detailed 375 disease subtypes that capture the diversity of COPD processes and their relationship with its clinical 376 manifestations. Another limitation of our study is the lack of replication of our results in independent 377 cohorts. Independent validation of this analysis is challenging since there are currently no other 378 cohorts that have collected the data required in enough subjects with advanced COPD. In the future, 379 with the additional generation of multi-omics data in NIH-funded studies such as SPIROMICS [69] 380 through the Trans-Omics in Precision Medicine (TOPMed) program [70], it will be possible to pursue 381 independent validation. In the meantime, we have pursued the next-best option, namely an extensive 382 robustness analysis using resampling approaches. A crucial objective left for future work is the 383 generation of distilled models that can reproduce our results in reduced datasets. Finally, cell type 384 proportions play a dual role in gene expression analyses, serving both as a potential manifestation of 385 the disease and a potential confounder [71]. This dual nature hinders the interpretability of gene expression results. Leveraging single cell RNA-seq data offers a way forward [72, 73]. By providing a 387 higher resolution view of individual cell populations and their associated gene expression patterns, it 388 becomes possible to discern between disease-associated shifts in cell populations and gene expression 389 changes within specific cell types. Therefore, another promising future direction for this work is its 390 application to single cell RNA-seq datasets. 391

## <sup>392</sup> 4 Methods

## <sup>393</sup> 4.1 Processing of clinical and phenotypic data

In the initial phase of preparing the input data for the VAE, we chose all the subjects who had 394 available clinical data and RNA-seq expression profiles, obtaining 3,628 samples. We classified each 395 feature as either numerical or categorical, and we devised different processing strategies to handle 396 the two groups of features. Among the categorical features, we excluded those with more than 10%397 of missing values across all subjects or where the most frequent category was present in more than 398 80% of subjects. The latter criterion was devised to avoid including features that are not sufficiently 300 informative of patient heterogeneity. Similarly, we excluded the numerical features with more than 400 10% missing values or with constant values. We then imputed the remaining missing values in the 401

categorical features by considering the most frequent category for each feature across all subjects.
The numerical missing values were imputed through KNN imputation with k equal to 10. As further
selection, we selected one representative variable among the groups of redundant categorical variables,
i.e., those with high similarly values (adjusted Rand score > 0.95). The resulting set of clinical
features selected for training the VAE is summarized in Supplementary Table 1.

## 407 4.2 Processing of expression data and differential expression analysis

From the raw read counts matrix we removed low expressed transcripts by selecting transcripts with 408 at least 1 CPM in more than 10 samples. Next, we processed the data with the DeSeq2 algorithm 409 [74], and removed batch effects with the function "removeBatchEffect" of the package limma [75] 410 Finally, to make the computations more manageable, and to perform a preliminary feature selection, 411 we selected only the genes that were loosely associated to at least one clinical feature in the dataset. 412 We assessed the significance of the relationships between each gene and each clinical feature, using 413 Spearman's correlation for numerical features and the Kruskal Wallis test for categorical ones. Genes 414 with at least one FDR-adjusted p-value below 0.001 were retained, yielding 5,979 transcripts. 415

To perform differential expression (DE) analysis we executed the DE pipeline of DeSeq2 starting 416 from the raw data. In brief, after basic data filtering we set up a design matrix with covariates 417 including sequencing batch, age, sex, race, and white blood cell proportions. As contrasts we choose 418 the membership to each of the three COPD branches (SEV, MOD, SYMPT) against the joined 419 population of the reference branches NORM1 and NORM2. From the three contrasts we obtained 420 three DE summary statistics. Next, we performed Gene Set Enrichment Analysis [76] with the 421 GSEApy python package [77]. Specifically, we ranked the genes by their negative log p-value score 422 multiplied by the sign of their log fold change (logFC). In this way, the genes that are significantly 423 upregulated in the contrast (low p-value, positive logFC) appear at the top of the ranking, while the 424 genes that are downregulated (low p-value, negative logFC) will appear at the bottom, providing a 425 coarse measure of their general state of differential activation. 426

### 427 4.3 Conditional Variational Autoencoder design

In order to find a shared latent space for expression and clinical features, we designed a conditional
VAE architecture with an "X" shape, similar to the X-VAE model described in [29], shown in Fig. 1
(d). The network takes as input a vector of concatenated RNA-seq read counts and clinical features
that have been normalized to be in the unit range.

The architecture consists of four subnetworks: two encoders  $\text{Encoder}_{\phi_1}$  and  $\text{Encoder}_{\phi_2}$ , and two decoders  $\text{Decoder}_{\theta_1}$  and  $\text{Decoder}_{\theta_2}$ . Each data mode  $x_1$  and  $x_2$ , along with the conditional variable c, is separately passed through an encoder network.

Each encoder network,  $\text{Encoder}_{\phi_i}(x_i, c)$  is composed of L layers where each layer l is defined as:

$$h_l^{(i)} = \text{ReLU}(\text{BatchNorm}(W_l^{(i)}h_{l-1}^{(i)} + b_l^{(i)})) \qquad i \in \{1, 2\}$$
(1)

436 with

$$h_0^{(i)} = \text{ReLU}(\text{BatchNorm}(W_0^{(i)}[x_i; c] + b_0^{(i)})) \qquad i \in \{1, 2\}$$
(2)

Here,  $h_l^{(i)}$  denotes the *l*-th layer's activations, BatchNorm is a batch normalization transformation,  $W_l^{(i)} \in \phi_i$  and  $b_l^{(i)} \in \phi_i$  are the weight matrix and bias terms of the *l*-th layer, ReLU is the activation function, and  $[\cdot; \cdot]$  is the concatenation operator.

440 These encoders transform their inputs into latent representations:

$$h_1 = \text{Encoder}_{\phi_1}(x_1, c) \tag{3}$$

$$h_2 = \text{Encoder}_{\phi_2}(x_2, c) \tag{4}$$

The two latent representations  $h_1$  and  $h_2$  are then concatenated to form a shared representation  $h = [h_1; h_2]$ . Two separate linear layers are used to project this representation into the parameters of a Gaussian distribution, forming the mean vector  $\mu(h)$  and the vector of standard deviations  $\sigma(h)$  of the latent distribution of the latent vector z.

$$\mu(h), \sigma(h) = \text{Linear}_{\mu}(h), \text{Linear}_{\sigma}(h)$$
(5)

For the decoder part, the sampled latent variable z is concatenated with the conditional variable c and passed through the decoder networks to generate the reconstructed data  $\hat{x}_1$  and  $\hat{x}_2$ .

$$\hat{x}_1 = \text{Decoder}_{\theta_1}(z, c) \tag{6}$$

$$\hat{x}_2 = \text{Decoder}_{\theta_2}(z, c). \tag{7}$$

Similarly, a decoder  $\text{Decoder}_{\theta_i}(z, c)$  is composed of L layers

$$h_{l}^{(i)} = \text{ReLU}(\text{BatchNorm}(V_{l}^{(i)}h_{l-1}^{(i)} + d_{l}^{(i)})) \qquad i \in \{1, 2\}$$
(8)

448 with

$$h_0^{(i)} = \text{ReLU}(\text{BatchNorm}(V_0^{(i)}[z;c] + d_0^{(i)})) \qquad i \in \{1,2\}.$$
(9)

As before,  $V_l^{(i)} \in \theta_i$  and  $d_l^{(i)} \in \theta_i$  are the weight matrix and bias terms of the *l*-th layer. Furthermore, the last layers of each decoder do not include a ReLU activation function to allow for negative outputs.

#### 452 4.3.1 The Evidence Lower Bound and Maximum Mean Discrepancy Loss

The training objective of our multimodal VAE is to maximize the Evidence Lower Bound (ELBO). 453 which in this case is a convex combination of the data-type-specific ELBO terms, governed by a 454 parameter  $\alpha_1$ . The reconstruction loss for each mode is calculated differently due to the nature 455 of their data. For the numerical data mode  $x_1$ , the Mean Squared Error (MSE) is used. For the 456 mixed data mode  $x_2$ , which contains numerical and categorical data, the loss is a convex combination 457 (controlled by a parameter  $\alpha_2$ ) of the MSE for the numerical part and the Categorical Cross-Entropy 458 for the categorical part. Furthermore, instead of the standard Kullback-Leibler (KL) divergence used 459 in the original formulation of VAE [35], we employ the Maximum Mean Discrepancy (MMD) measure 460 to regularize the model as proposed in the InfoVAE formulation [78]. Similarly to KL divergence, 461 MMD is a distance measure between two probability distributions. However, MMD only depends on 462 a set of statistics evaluated from the two distributions, and therefore it does not require the explicit 463 evaluation of their analytical form. In the Gaussian case, MMD calculation is done by embedding 464 the distributions in a Reproducing Kernel Hilbert Space (RKHS) identified by their average and 465 standard deviation, and by computing the distance between these statistics [79]. The ELBO  $\mathcal{L}_{\text{MMD}}$ 466 has the form 467

$$\mathcal{L}_{\text{MMD}}(x_1, x_2, c, \theta, \phi) = \alpha_1 \cdot \mathbb{E}_{q_{\phi}(z|x_1, x_2, c)} [\text{MSE}(x_1, \text{Decoder}_{\theta_1}(z, c))] + (1 - \alpha_1) \cdot \left( \mathbb{E}_{q_{\phi}(z|x_1, x_2, c)} [\alpha_2 \cdot \text{MSE}(x_{2_{\text{num}}}, \text{Decoder}_{\theta_{2_{\text{num}}}}(z, c)) \right) + (1 - \alpha_2) \cdot \text{CCE}(x_{2_{\text{cat}}}, \text{Decoder}_{\theta_{2_{\text{cat}}}}(z, c))] \right) - \gamma \cdot \text{MMD}(q_{\phi}(z|x_1, x_2, c), p_{\theta}(z|c))$$
(10)

Here,  $x_{2_{\text{num}}}$  represents the numerical part and  $x_{2_{\text{cat}}}$  represents the categorical part of the second data mode  $x_2$ . The expected values  $\mathbb{E}_{q_{\phi}(z|x_1,x_2,c)}$  are approximated by a single sampling of  $z \sim \mathcal{N}(\mu(h), \sigma(h))$ . Decoder $_{\theta_{2_{\text{num}}}}(z, c)$  and Decoder $_{\theta_{2_{\text{cat}}}}(z, c)$  are the reconstructed numerical and

categorical parts of the data respectively, and CCE denotes the average Categorical Cross-Entropy loss across all the categorical variables.  $MMD(q_{\phi}(z|x), p_{\theta}(z))$  measures the dissimilarity between the approximate posterior  $q_{\phi}(z|x)$  and the prior  $p_{\theta}(z)$  in terms of their mean embeddings in the RKHS.

#### 474 4.3.2 Optimization

Optimization was performed with the ADAM optimizer [80]. In all our tests the full dataset is split 475 in 80% training samples, 10% validation samples and 10% test samples. To identify the optimal 476 hyperparameters (number and size of hidden layers, the learning rate, and training batch size), we 477 performed hyperparameter optimization with ASHA (Asynchronous Successive Halving Algorithm), a 478 scheme for parallel optimization equipped with greedy early stopping strategies to rule out inefficient 479 hyperparameter configurations [81]. In the final optimal configuration the encoder subnetwork for 480 processing the expression data has 2 hidden layers of dimensions 1024 and 512 neurons, while the 481 encoder subnetworks for processing the clinical data has 1 hidden layer of dimension 64 neurons. The 482 decoder networks are constrained to mirror the encoder structure in reverse. The mini-batch size is 483 128.484

### 485 4.4 Prediction of future outcomes from PIPs

The prediction task was performed by training a set of random forest (RF) classifiers using multiple input embeddings and output disease outcomes, as listed in the main text.

The embeddings of MOFA [22] were calculated by running the mofapy python package, feeding the expression and clinical data as input and by setting 30 as the number of hidden factors. The MOFA embeddings were defined as the estimated means of the factors obtained after fitting the model.

For ease of comparison of performances, we considered a set of binary outcomes. COPD outcomes 492 that are measured as continuous variables were transformed to binary variables by thresholding. The 493 selection of thresholds was guided by practical considerations to ensure a balanced representation 494 of positive and negative examples. The considered target variables are the following: (1)  $\Delta FEV_1$ 495 % of pred. (P3<P2): subjects with more than 10% decrease of FEV<sub>1</sub> percent predicted between 496 Phase 2 and Phase 3 (positive class) compared to subjects with more than 10% increase (negative 497 class) (N=331); (2) inc. bronchitis (P3): incident chronic bronchitis in Phase 3, restricted to 498 individuals without chronic bronchitis in Phase 2 (N=1,087); (3) exacerbations (P3): frequency 499 of exacerbations in Phase 3 greater than 0 (N=1,251); (4)  $\Delta$  exacerbation frequency (P3>P2): 500 frequency of exacerbations in Phase 3 greater than Phase 2 (N=1.251); (5) severe exacerbations 501 (P3): presence of severe exacerbations in Phase 3 (N=1,250); (6)  $\Delta$  severe exacerbations (P3>P2): 502 presence of severe exacerbations in Phase 3 in subjects who did not experience severe exacerbations 503 in Phase 2 (N=1,164); (7)  $\Delta$ mMRC (P3>P2): increased mMRC dyspnea score in Phase 3 compared 504 to Phase 2 (N=1,183); (8)  $\Delta$ SF-36 (P3<P2): decrease of SF-36 score between Phase 2 and Phase 505 3 (N=1,251); (9,10) mortality (3/5yr): all-cause mortality at 3 and 5 years (N=3,361/3,347). We506 set up each RF classifier with 100 decision trees. For a more robust performance assessment that 507 is not too sensitive to a specific train/test split of the dataset, we conducted a stratified 5-fold 508 cross-validation, repeated 3 times. For each split, we performed three steps: (1) we normalized the 509 whole dataset according to the statistics obtained from the current training set; (2) since most clinical 510 outcomes have highly unbalanced class distributions, we performed SMOTE oversampling [82] of 511 the minority class, using the *imblearn* python package [83]; (3) we trained the classifier with the 512 resulting data. The values shown in Table 1 are the summary statistics obtained by the 5-fold splits 513 repeated 3 times, for a total of 15 performance values for each prediction. The significance values are 514 obtained by performing t-tests between the performance values obtained by the best embedding and 515 the second-best embedding. 516

## <sup>517</sup> 4.5 Construction of principal graph

To build the principal graph describing the distance relationships between observations in the 518 embedding space, we used the elPiGraph method [36]. We used default parameters, except for the 519 maximum number of nodes which was set to 30 to increase resolution. Also we set the "collapse" 520 argument to True, in order to merge the small and noisy branches within their main branch. All the 521 2D embeddings shown in Fig. 2 are evaluated with a modified version of the elPiGraph function 522 "visualize eltree with data". In brief, this function first produces a 2D embedding of the principal 523 graph using the Kamada-Kawai layout algorithm [84]. Next, it distributes all the data points across 524 the branches according to their calculated projections. Finally, to improve clarity each point is 525 scattered randomly in the direction orthogonal to the branch by an extent controlled by a fixed 526 parameter. 527

### <sup>528</sup> 4.6 Processing of LFU and mortality data

To visualize the trends in Fig. 4 (a), we considered all the long-term follow-up (LFU) survey data 529 that were compiled after Phase 2 of the COPDGene study (as of August 2022). Since the time points 530 refer to the time the survey was compiled, we considered as the interval range of each data point the 531 6 months prior to the compile date, unless another survey was compiled by the same subject less 532 than 6 months earlier. In that case, the time interval is the time span occurring between the two 533 surveys. To analyze the risk of increased exacerbations over time, we set up a Poisson regression 534 model, controlling for the age, sex, and race covariates. The model was fit through the glmfit R 535 function, using a log link function. We also tested an alternative mixed effect model where subject 536 identity was included as a random effect, obtaining similar results. To estimate mortality at 3 and 5 years, we considered the COPDGene all-cause mortality data as of October 2022. To implement the 538 Cox proportional hazard model of mortality we used the *lifelines* python package [85]. 539

### <sup>540</sup> 4.7 Evaluation of distance correlation (dCorr)

The similarity between two sets of N vectors embedded in two spaces can be estimated by modeling each vector set as the N realizations of a multivariate random variable. From this standpoint, the similarity between the two sets is equivalent to the level of statistical dependency between the two variables. dCorr is an extension of the Pearson correlation to multivariate settings and it ranges between 0 (statistical independence) and 1 (linear dependency) [49]. Furthermore, dCorr is invariant to rigid transformations applied to either of the two spaces (e.g. rotations). This makes it an ideal tool for assessing the similarity between the two sets of vector embeddings. dCorr is estimated as follows [86]:

<sup>549</sup> let X and Y be two d-dimensional vector sets. Define  $a_{ij}$  and  $b_{ij}$  to be the Euclidean distances <sup>550</sup> between the *i*th and *j*th elements of X and Y, respectively. We then form the centered distance <sup>551</sup> matrices A and B as follows:

$$A_{ij} = a_{ij} - \bar{a}_{i.} - \bar{a}_{.j} + \bar{a}_{..}, \quad B_{ij} = b_{ij} - \bar{b}_{i.} - \bar{b}_{.j} + \bar{b}_{..},$$

552 where

$$\bar{a}_{i.} = \frac{1}{n} \sum_{k=1}^{n} a_{ik}, \quad \bar{a}_{.j} = \frac{1}{n} \sum_{k=1}^{n} a_{kj}, \quad \bar{a}_{..} = \frac{1}{n^2} \sum_{k,l=1}^{n} a_{kl},$$
$$\bar{b}_{i.} = \frac{1}{n} \sum_{k=1}^{n} b_{ik}, \quad \bar{b}_{.j} = \frac{1}{n} \sum_{k=1}^{n} b_{kj}, \quad \bar{b}_{..} = \frac{1}{n^2} \sum_{k,l=1}^{n} b_{kl},$$

The distance covariance (dCov) and distance correlation (dCorr) are defined as

$$dCov(X,Y) = \sqrt{\frac{1}{n^2} \sum_{i,j=1}^n A_{ij} B_{ij}},$$
$$dCorr(X,Y) = \frac{dCov(X,Y)}{\sqrt{dCov(X,X) \cdot dCov(Y,Y)}}$$

The distance covariance correlation was evaluated with the python package hyppo [87].

### 4.8 Evaluation of the branch purity with respect to data resamplings

Let us consider a set of n data points with branch labels  $Y = \{y_1, y_2, ..., y_n\}$ , where each  $y_i$  belongs to one of K branches. In a resampled embedding we produce a new branch assignment  $Y' = \{y'_1, y'_2, ..., y'_n\}$ , where each  $y'_i$  belongs to one of K' branches, with K not necessarily equal to K'. The purity of branch k in the original labeling Y with respect to the resampled branch labels Y' is defined as

Purity
$$(k; Y, Y') = \frac{1}{N_k} \max_{k'=1,\dots,K'} |\{i : y_i = k\} \cap \{i : y'_i = k'\}|$$

where  $N_k = |\{i : y_i = k\}|$  and |.| denotes the cardinality of a set. This value measures the number of items in the k-th branch that belong to the most common resampled branch. Purity is a fraction between 0 and 1, where higher values indicate stronger alignment between the original and resampled branch assignments.

## 560 5 Data Availability

All COPDGene data for the analysis are available in dbGaP accession number phs000179.v6.p2. The data generated in this study has been deposited in the Zenodo repository, accessible via the DOI: 10.5281/zenodo.10431493.

# <sup>564</sup> 6 Code Availability

The code used to reproduce the analyses in this study is available in the GitHub repository accessible via the following URL: https://github.com/reemagit/joint\_subtyping\_vae.

## 567 References

- [1] Rafael Lozano, Mohsen Naghavi, Kyle Foreman, Stephen Lim, Kenji Shibuya, Victor Aboyans, Jerry Abraham, Timothy Adair, Rakesh Aggarwal, Stephanie Y Ahn, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. *The lancet*, 380(9859):2095–2128, 2012.
- [2] Rosa Faner and Alvar Agusti. Multilevel, dynamic chronic obstructive pulmonary disease
  heterogeneity. a challenge for personalized medicine. Annals of the American Thoracic Society,
  13(Supplement 5):S466–S470, 2016.
- [3] Peter J Castaldi, Adel Boueiz, Jeong Yun, Raul San Jose Estepar, James C Ross, George Washko,
  Michael H Cho, Craig P Hersh, Gregory L Kinney, Kendra A Young, et al. Machine learning
  characterization of copd subtypes: insights from the copdgene study. *Chest*, 157(5):1147–1157,
  2020.
- [4] Suchi Saria and Anna Goldenberg. Subtyping: What it is and its role in precision medicine.
   *IEEE Intelligent Systems*, 30(4):70–75, 2015.

 [5] Kristina L Buschur, Craig Riley, Aabida Saferali, Peter Castaldi, Grace Zhang, Francois Aguet, Kristin G Ardlie, Peter Durda, W Craig Johnson, Silva Kasela, et al. Distinct copd subtypes in former smokers revealed by gene network perturbation analysis. *Respiratory Research*, 24(1): 1–12, 2023.

- [6] James C Ross, Peter J Castaldi, Michael H Cho, Craig P Hersh, Farbod N Rahaghi, Gonzalo V
  Sánchez-Ferrero, Margaret M Parker, Augusto A Litonjua, David Sparrow, Jennifer G Dy,
  et al. Longitudinal modeling of lung function trajectories in smokers with and without chronic
  obstructive pulmonary disease. American journal of respiratory and critical care medicine, 198
  (8):1033-1042, 2018.
- [7] Pierre-Régis Burgel, Jean-Louis Paillasseur, Wim Janssens, Jacques Piquet, Gerben Ter Riet,
   Judith Garcia-Aymerich, Borja Cosio, Per Bakke, Milo A Puhan, Arnulf Langhammer, et al.
   A simple algorithm for the identification of clinical copd phenotypes. *European Respiratory Journal*, 50(5), 2017.
- [8] Peter J Castaldi, Jennifer Dy, James Ross, Yale Chang, George R Washko, Douglas Curran-Everett, Andre Williams, David A Lynch, Barry J Make, James D Crapo, et al. Cluster analysis in the copdgene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. *Thorax*, 69(5):416–423, 2014.
- [9] Judith Garcia-Aymerich, Federico P Gómez, Marta Benet, Eva Farrero, Xavier Basagana, Angel Gayete, Carles Paré, Xavier Freixa, Jaume Ferrer, Antoni Ferrer, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (copd) subtypes. *Thorax*, 66(5):430–437, 2011.
- Lucas A Gillenwater, Shahab Helmi, Evan Stene, Katherine A Pratte, Yonghua Zhuang, Ronald P
   Schuyler, Leslie Lange, Peter J Castaldi, Craig P Hersh, Farnoush Banaei-Kashani, et al. Multi omics subtyping pipeline for chronic obstructive pulmonary disease. *Plos one*, 16(8):e0255337,
   2021.
- [11] Yale Chang, Kimberly Glass, Yang-Yu Liu, Edwin K Silverman, James D Crapo, Ruth Tal Singer, Russ Bowler, Jennifer Dy, Michael Cho, and Peter Castaldi. Copd subtypes identified by
   network-based clustering of blood gene expression. *Genomics*, 107(2-3):51–58, 2016.
- [12] Zili Zhang, Jian Wang, Yuanyuan Li, Fei Liu, Lingdan Chen, Shunping He, Fanjie Lin, Xinguang
   Wei, Yaowei Fang, Qiongqiong Li, et al. Proteomics and metabolomics profiling reveal panels of
   circulating diagnostic biomarkers and molecular subtypes in stable copd. *Respiratory Research*,
   24(1):73, 2023.
- [13] Andrew Gregory, Zhonghui Xu, Katherine Pratte, Sool Lee, Congjian Liu, Robert Chase, Jeong
  Yun, Aabida Saferali, Craig P Hersh, Russell Bowler, et al. Clustering-based copd subtypes have
  distinct longitudinal outcomes and multi-omics biomarkers. *BMJ Open Respiratory Research*, 9
  (1):e001182, 2022.
- [14] Margaret F Ragland, Christopher J Benway, Sharon M Lutz, Russell P Bowler, Julian Hecker,
  John E Hokanson, James D Crapo, Peter J Castaldi, Dawn L DeMeo, Craig P Hersh, et al.
  Genetic advances in chronic obstructive pulmonary disease. insights from copdgene. American *journal of respiratory and critical care medicine*, 200(6):677–690, 2019.
- [15] Jian Wang, Margaret R Spitz, Christopher I Amos, Anna V Wilkinson, Xifeng Wu, and Sanjay
   Shete. Mediating effects of smoking and chronic obstructive pulmonary disease on the relation
   between the chrna5-a3 genetic locus and lung cancer risk. *Cancer*, 116(14):3458–3462, 2010.
- [16] Ivy Reichert Vital da Silva, Cintia Laura Pereira de Araujo, Gilson Pires Dorneles, Alessandra Peres, Andreia Luciana Bard, Gustavo Reinaldo, Paulo José Zimermann Teixeira, Pedro Dal Lago, and Viviane Rostirola Elsner. Exercise-modulated epigenetic markers and inflammatory response in copd individuals: A pilot study. *Respiratory physiology & neurobiology*, 242:89–95, 2017.

- [17] NM Siafakas and EG Tzortzaki. Few smokers develop copd. why? Respiratory medicine, 96(8):
   615–624, 2002.
- [18] Peter J Castaldi, Marta Benet, Hans Petersen, Nicholas Rafaels, James Finigan, Matteo Paoletti, H Marike Boezen, Judith M Vonk, Russell Bowler, Massimo Pistolesi, et al. Do copd subtypes really exist? copd heterogeneity and clustering in 10 independent cohorts. *Thorax*, 72(11): 998–1006, 2017.
- [19] Chuan-Xing Li, Craig E Wheelock, C Magnus Sköld, and Åsa M Wheelock. Integration of
   multi-omics datasets enables molecular classification of copd. *European Respiratory Journal*, 51
   (5), 2018.
- [20] Enrico Maiorino and Joseph Loscalzo. Phenomics and robust multiomics data for cardiovascular disease subtyping. Arteriosclerosis, Thrombosis, and Vascular Biology, 43(7):1111–1123, 2023.
- [21] Laura Cantini, Pooya Zakeri, Celine Hernandez, Aurelien Naldi, Denis Thieffry, Elisabeth Remy,
   and Anaïs Baudot. Benchmarking joint multi-omics dimensionality reduction approaches for the
   study of cancer. Nature communications, 12(1):124, 2021.
- [22] Ricard Argelaguet, Britta Velten, Damien Arnol, Sascha Dietrich, Thorsten Zenz, John C
  Marioni, Florian Buettner, Wolfgang Huber, and Oliver Stegle. Multi-omics factor analysis—a
  framework for unsupervised integration of multi-omics data sets. *Molecular systems biology*, 14
  (6):e8124, 2018.
- [23] Ronglai Shen, Adam B Olshen, and Marc Ladanyi. Integrative clustering of multiple genomic
   data types using a joint latent variable model with application to breast and lung cancer subtype
   analysis. *Bioinformatics*, 25(22):2906–2912, 2009.
- [24] Bo Wang, Aziz M Mezlini, Feyyaz Demir, Marc Fiume, Zhuowen Tu, Michael Brudno, Benjamin
   Haibe-Kains, and Anna Goldenberg. Similarity network fusion for aggregating data types on a
   genomic scale. Nature methods, 11(3):333–337, 2014.
- [25] Junxiang Chen, Xu Zhonghui, Li Sun, Ke Yu, Craig P Hersh, Adel Boueiz, John Hokanson,
  Frank C Sciurba, Edwin K Silverman, Peter J Castaldi, et al. Deep learning integration of chest
  ct imaging and gene expression identifies novel aspects of copd. medRxiv, pages 2022–09, 2022.
- [26] Indhupriya Subramanian, Srikant Verma, Shiva Kumar, Abhay Jere, and Krishanpal Anamika.
   Multi-omics data integration, interpretation, and its application. *Bioinformatics and biology insights*, 14:1177932219899051, 2020.
- [27] Evangelina López de Maturana, Lola Alonso, Pablo Alarcón, Isabel Adoración Martín-Antoniano,
   Silvia Pineda, Lucas Piorno, M Luz Calle, and Núria Malats. Challenges in the integration of
   omics and non-omics data. *Genes*, 10(3):238, 2019.
- [28] Dongjin Leng, Linyi Zheng, Yuqi Wen, Yunhao Zhang, Lianlian Wu, Jing Wang, Meihong
   Wang, Zhongnan Zhang, Song He, and Xiaochen Bo. A benchmark study of deep learning-based
   multi-omics data fusion methods for cancer. *Genome Biology*, 23(1):1–32, 2022.
- [29] Nikola Simidjievski, Cristian Bodnar, Ifrah Tariq, Paul Scherer, Helena Andres Terre, Zohreh
   Shams, Mateja Jamnik, and Pietro Liò. Variational autoencoders for cancer data integration:
   design principles and computational practice. Frontiers in genetics, 10:1205, 2019.
- [30] Xiaoyu Zhang, Jingqing Zhang, Kai Sun, Xian Yang, Chengliang Dai, and Yike Guo. Integrated multi-omics analysis using variational autoencoders: application to pan-cancer classification. In 2019 IEEE International Conference on Bioinformatics and Biomedicine (BIBM), pages 765-769. IEEE, 2019.

- [31] Tianwei Yu. Aime: Autoencoder-based integrative multi-omics data embedding that allows for
   confounder adjustments. *PLoS Computational Biology*, 18(1):e1009826, 2022.
- [32] Elizabeth A Regan, John E Hokanson, James R Murphy, Barry Make, David A Lynch, Terri H
  Beaty, Douglas Curran-Everett, Edwin K Silverman, and James D Crapo. Genetic epidemiology
  of copd (copdgene) study design. COPD: Journal of Chronic Obstructive Pulmonary Disease, 7
  (1):32–43, 2011.
- [33] Sören Richard Stahlschmidt, Benjamin Ulfenborg, and Jane Synnergren. Multimodal deep
   learning for biomedical data fusion: a review. *Briefings in Bioinformatics*, 23(2):bbab569, 2022.
- [34] Jiquan Ngiam, Aditya Khosla, Mingyu Kim, Juhan Nam, Honglak Lee, and Andrew Y Ng.
   Multimodal deep learning. In *Proceedings of the 28th international conference on machine learning (ICML-11)*, pages 689–696, 2011.
- [35] Diederik P Kingma and Max Welling. Auto-encoding variational bayes. arXiv preprint
   arXiv:1312.6114, 2013.
- [36] Sergey E Golovenkin, Jonathan Bac, Alexander Chervov, Evgeny M Mirkes, Yuliya V Orlova,
   Emmanuel Barillot, Alexander N Gorban, and Andrei Zinovyev. Trajectories, bifurcations, and
   pseudo-time in large clinical datasets: Applications to myocardial infarction and diabetes data.
   *GigaScience*, 9(11):giaa128, 2020.
- [37] Diederik P Kingma, Max Welling, et al. An introduction to variational autoencoders. Foundations
   and Trends (R) in Machine Learning, 12(4):307–392, 2019.
- [38] Ian Goodfellow, Yoshua Bengio, and Aaron Courville. Deep learning. MIT press, 2016.
- [39] Christos Louizos, Kevin Swersky, Yujia Li, Max Welling, and Richard Zemel. The variational
   fair autoencoder. arXiv preprint arXiv:1511.00830, 2015.
- [40] AJ Bell, S Ram, WW Labaki, S Murray, E Kazerooni, S Galban, FJ Martinez, C Hatt, JM Wang,
  E Mirkes, et al. Clinical trajectory analysis with longitudinal validation in copd: A copdgene
  study. In D97. IMPACT OF COPD ACROSS THE LIFESPAN, pages A6589–A6589. American
  Thoracic Society, 2023.
- [41] Alexander Chervov and Andrei Zinovyev. Clinical trajectories estimated from bulk tumoral molecular profiles using elastic principal trees. In 2021 International Joint Conference on Neural Networks (IJCNN), pages 1–9. IEEE, 2021.
- [42] John R. Hurst, Jørgen Vestbo, Antonio Anzueto, Nicholas Locantore, Hana Müllerova, Ruth Tal-Singer, Bruce Miller, David A. Lomas, Alvar Agusti, William MacNee, Peter Calverley, Stephen Rennard, Emiel F.M. Wouters, and Jadwiga A. Wedzicha. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine, 363(12):1128–1138, 2010. doi:10.1056/NEJMoa0909883. URL https://doi.org/10.1056/NEJMoa0909883. PMID: 20843247.
- [43] Emily S Wan, Peter J Castaldi, Michael H Cho, John E Hokanson, Elizabeth A Regan, Barry J
  Make, Terri H Beaty, MeiLan K Han, Jeffrey L Curtis, Douglas Curran-Everett, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (prism) in copdgene. *Respiratory research*, 15(1):1–13, 2014.
- [44] Peter J Castaldi, Zhonghui Xu, Kendra A Young, John E Hokanson, David A Lynch, Stephen M Humphries, James C Ross, Michael H Cho, Craig P Hersh, James D Crapo, et al. Copd heterogeneity and progression: Emphysema-predominant and non-emphysema-predominant disease. *American Journal of Epidemiology*, page kwad114, 2023.

- [45] Jing Shi and Michael G Walker. Gene set enrichment analysis (gsea) for interpreting gene expression profiles. *Current Bioinformatics*, 2(2):133–137, 2007.
- [46] Arthur Liberzon, Aravind Subramanian, Reid Pinchback, Helga Thorvaldsdóttir, Pablo Tamayo,
  and Jill P Mesirov. Molecular signatures database (msigdb) 3.0. *Bioinformatics*, 27(12):
  1739–1740, 2011.
- [47] Sharon Mumby and Ian M Adcock. Recent evidence from omic analysis for redox signalling and
   mitochondrial oxidative stress in copd. Journal of Inflammation, 19(1):10, 2022.
- [48] Barry R Imhoff and Jason M Hansen. Extracellular redox status regulates nrf2 activation
   through mitochondrial reactive oxygen species. *Biochemical Journal*, 424(3):491–500, 2009.
- [49] Gábor J Székely, Maria L Rizzo, and Nail K Bakirov. Measuring and testing dependence by
   correlation of distances. 2007.
- [50] Yonghua Zhuang, Fuyong Xing, Debashis Ghosh, Brian D Hobbs, Craig P Hersh, Farnoush
  Banaei-Kashani, Russell P Bowler, and Katerina Kechris. Deep learning on graphs for multi-omics
  classification of copd. *Plos one*, 18(4):e0284563, 2023.
- <sup>728</sup> [51] Junxiang Chen, Zhonghui Xu, Li Sun, Ke Yu, Craig P Hersh, Adel Boueiz, John E Hokanson,
  <sup>729</sup> Frank C Sciurba, Edwin K Silverman, Peter J Castaldi, et al. Deep learning integration of chest
  <sup>730</sup> computed tomography imaging and gene expression identifies novel aspects of copd. *Chronic Obstructive Pulmonary Diseases (Miami, Fla.)*, 2023.
- [52] Alvar Agusti, Elisabeth Bel, Mike Thomas, Claus Vogelmeier, Guy Brusselle, Stephen Holgate,
  Marc Humbert, Paul Jones, Peter G Gibson, Jørgen Vestbo, et al. Treatable traits: toward
  precision medicine of chronic airway diseases. *European Respiratory Journal*, 47(2):410–419,
  2016.
- [53] Junxiang Chen, Michael Cho, Edwin K Silverman, John E Hokanson, Greg L Kinney, James D Crapo, Stephen Rennard, Jennifer Dy, and Peter Castaldi. Turning subtypes into disease axes to improve prediction of copd progression. *Thorax*, 74(9):906–909, 2019.

[54] Mark T Dransfield, Ken M Kunisaki, Matthew J Strand, Antonio Anzueto, Surya P Bhatt,
Russell P Bowler, Gerard J Criner, Jeffrey L Curtis, Nicola A Hanania, Hrudaya Nath, et al.
Acute exacerbations and lung function loss in smokers with and without chronic obstructive
pulmonary disease. American journal of respiratory and critical care medicine, 195(3):324–330,
2017.

- [55] David MG Halpin, Marc Decramer, Bartolome R Celli, Achim Mueller, Norbert Metzdorf, and
   Donald P Tashkin. Effect of a single exacerbation on decline in lung function in copd. *Respiratory medicine*, 128:85–91, 2017.
- [56] David MG Halpin, Marc Decramer, Bartolome Celli, Steven Kesten, Dacheng Liu, and Donald P
   Tashkin. Exacerbation frequency and course of copd. International journal of chronic obstructive
   *pulmonary disease*, pages 653–661, 2012.
- [57] GC Donaldson, Terence AR Seemungal, A Bhowmik, and JA1746193 Wedzicha. Relationship
   between exacerbation frequency and lung function decline in chronic obstructive pulmonary
   disease. *Thorax*, 57(10):847–852, 2002.
- [58] Prescott G Woodruff, R Graham Barr, Eugene Bleecker, Stephanie A Christenson, David Couper,
  Jeffrey L Curtis, Natalia A Gouskova, Nadia N Hansel, Eric A Hoffman, Richard E Kanner,
  et al. Clinical significance of symptoms in smokers with preserved pulmonary function. New
  England Journal of Medicine, 374(19):1811–1821, 2016.

[59] Elizabeth A Regan, David A Lynch, Douglas Curran-Everett, Jeffrey L Curtis, John HM
Austin, Philippe A Grenier, Hans-Ulrich Kauczor, William C Bailey, Dawn L DeMeo, Richard H
Casaburi, et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA *internal medicine*, 175(9):1539–1549, 2015.

[60] Brian D Hobbs and Craig P Hersh. Integrative genomics of chronic obstructive pulmonary disease. Biochemical and biophysical research communications, 452(2):276–286, 2014.

[61] Timothy M Bahr, Grant J Hughes, Michael Armstrong, Rick Reisdorph, Christopher D Coldren,
Michael G Edwards, Christina Schnell, Ross Kedl, Daniel J LaFlamme, Nichole Reisdorph, et al.
Peripheral blood mononuclear cell gene expression in chronic obstructive pulmonary disease.
American journal of respiratory cell and molecular biology, 49(2):316–323, 2013.

767 [62] Aran Singanayagam, Su-Ling Loo, Maria Calderazzo, Lydia J Finney, Maria-Belen Trujillo Tor768 ralbo, Eteri Bakhsoliani, Jason Girkin, Punnam Veerati, Prabuddha S Pathinayake, Kristy S
769 Nichol, et al. Antiviral immunity is impaired in copd patients with frequent exacerbations.
770 American Journal of Physiology-Lung Cellular and Molecular Physiology, 317(6):L893–L903,
771 2019.

[63] Yessica D Torres-Ramos, Araceli Montoya-Estrada, Alberto M Guzman-Grenfell, Javier Mancilla-Ramirez, Beatriz Cardenas-Gonzalez, Salvador Blanco-Jimenez, Jose D Sepulveda-Sanchez, Alejandra Ramirez-Venegas, and Juan J Hicks. Urban pm2. 5 induces ros generation and rbc damage in copd patients. Front Biosci (Elite Ed), 3:808–817, 2011.

[64] Aravind T Reddy, Sowmya P Lakshmi, Asoka Banno, and Raju C Reddy. Role of gpx3 in
 pparγ-induced protection against copd-associated oxidative stress. Free Radical Biology and
 Medicine, 126:350–357, 2018.

[65] I Rahman and IM Adcock. Oxidative stress and redox regulation of lung inflammation in copd.
 *European respiratory journal*, 28(1):219–242, 2006.

[66] Isaac K Sundar, Sangwoon Chung, Jae-Woong Hwang, Gnanapragasam Arunachalam, Suzanne Cook, Hongwei Yao, Witold Mazur, Vuokko L Kinnula, Aron B Fisher, and Irfan Rahman. Peroxiredoxin 6 differentially regulates acute and chronic cigarette smoke-mediated lung inflammatory response and injury. *Experimental lung research*, 36(8):451–462, 2010.

[67] Saleela M Ruwanpura, Louise McLeod, Alistair Miller, Jessica Jones, Ross Vlahos, Georg Ramm,
 Anthony Longano, Philip G Bardin, Steven Bozinovski, Gary P Anderson, et al. Deregulated
 stat3 signaling dissociates pulmonary inflammation from emphysema in gp130 mutant mice.
 American Journal of Physiology-Lung Cellular and Molecular Physiology, 302(7):L627–L639,
 2012.

[68] Liang Yew-Booth, Mark A Birrell, Ming Sum Lau, Katie Baker, Victoria Jones, Iain Kilty, and
Maria G Belvisi. Jak-stat pathway activation in copd. *European Respiratory Journal*, 46(3):
843–845, 2015.

[69] David Couper, Lisa M LaVange, MeiLan Han, R Graham Barr, Eugene Bleecker, Eric A Hoffman,
Richard Kanner, Eric Kleerup, Fernando J Martinez, Prescott G Woodruff, et al. Design of the
subpopulations and intermediate outcomes in copd study (spiromics). *Thorax*, 69(5):492–495,
2014.

[70] Daniel Taliun, Daniel N Harris, Michael D Kessler, Jedidiah Carlson, Zachary A Szpiech, Raul Torres, Sarah A Gagliano Taliun, André Corvelo, Stephanie M Gogarten, Hyun Min Kang, et al. Sequencing of 53,831 diverse genomes from the nhlbi topmed program. *Nature*, 590(7845): 290–299, 2021.

[71] Yohannes Tesfaigzi, Jeffrey L Curtis, Irina Petrache, Francesca Polverino, Farrah Kheradmand,
 Ian M Adcock, and Stephen I Rennard. Does copd originate from different cell types? American
 Journal of Respiratory Cell and Molecular Biology, (ja), 2023.

- [72] Maor Sauler, John E McDonough, Taylor S Adams, Neeharika Kothapalli, Thomas Barnthaler,
  Rhiannon B Werder, Jonas C Schupp, Jessica Nouws, Matthew J Robertson, Cristian Coarfa,
  et al. Characterization of the copd alveolar niche using single-cell rna sequencing. Nature
  communications, 13(1):494, 2022.
- [73] Qiqing Huang, Yuanyuan Wang, Lili Zhang, Wei Qian, Shaoran Shen, Jingshen Wang, Shuang-shuang Wu, Wei Xu, Bo Chen, Mingyan Lin, et al. Single-cell transcriptomics highlights immunological dysregulations of monocytes in the pathobiology of copd. *Respiratory Research*, 23(1):367, 2022.
- [74] Michael Love, Simon Anders, and Wolfgang Huber. Differential analysis of count data-the
   deseq2 package. *Genome Biol*, 15(550):10–1186, 2014.
- [75] Matthew E Ritchie, Belinda Phipson, DI Wu, Yifang Hu, Charity W Law, Wei Shi, and Gordon K
   Smyth. limma powers differential expression analyses for rna-sequencing and microarray studies.
   *Nucleic acids research*, 43(7):e47–e47, 2015.
- [76] Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert,
  Michael A Gillette, Amanda Paulovich, Scott L Pomeroy, Todd R Golub, Eric S Lander,
  et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide
  expression profiles. *Proceedings of the National Academy of Sciences*, 102(43):15545–15550, 2005.
- [77] Zhuoqing Fang, Xinyuan Liu, and Gary Peltz. Gseapy: a comprehensive package for performing
   gene set enrichment analysis in python. *Bioinformatics*, 39(1):btac757, 2023.
- [78] Shengjia Zhao, Jiaming Song, and Stefano Ermon. Infovae: Balancing learning and inference in variational autoencoders. In *Proceedings of the aaai conference on artificial intelligence*, volume 33, pages 5885–5892, 2019.
- [79] Arthur Gretton, Karsten Borgwardt, Malte Rasch, Bernhard Schölkopf, and Alex Smola. A
   kernel method for the two-sample-problem. Advances in neural information processing systems,
   19, 2006.
- [80] Diederik P Kingma and Jimmy Ba. Adam: A method for stochastic optimization. arXiv preprint
   arXiv:1412.6980, 2014.
- [81] Liam Li, Kevin Jamieson, Afshin Rostamizadeh, Ekaterina Gonina, Jonathan Ben-Tzur, Moritz
   Hardt, Benjamin Recht, and Ameet Talwalkar. A system for massively parallel hyperparameter
   tuning. Proceedings of Machine Learning and Systems, 2:230–246, 2020.
- [82] Nitesh V Chawla, Kevin W Bowyer, Lawrence O Hall, and W Philip Kegelmeyer. Smote:
  synthetic minority over-sampling technique. Journal of artificial intelligence research, 16:
  321–357, 2002.
- [83] Guillaume Lemaître, Fernando Nogueira, and Christos K. Aridas. Imbalanced-learn: A python
   toolbox to tackle the curse of imbalanced datasets in machine learning. Journal of Machine
   Learning Research, 18(17):1-5, 2017. URL http://jmlr.org/papers/v18/16-365.html.
- [84] Tomihisa Kamada, Satoru Kawai, et al. An algorithm for drawing general undirected graphs.
   *Information processing letters*, 31(1):7–15, 1989.
- [85] Cameron Davidson-Pilon. lifelines: survival analysis in python. Journal of Open Source Software,
   4(40):1317, 2019. doi:10.21105/joss.01317. URL https://doi.org/10.21105/joss.01317.

[86] Gábor J Székely and Maria L Rizzo. Partial distance correlation with methods for dissimilarities.
 2014.

[87] Sambit Panda, Satish Palaniappan, Junhao Xiong, Eric W. Bridgeford, Ronak Mehta, Cencheng
 Shen, and Joshua T. Vogelstein. hyppo: A comprehensive multivariate hypothesis testing python
 package, 2020.

# **349** 7 Author contributions

EM, PJC and KG conceptualized the study and designed the project. EM led the data analysis and
code implementation. MDM, ZX, RTC, and JHY contributed to the data processing steps. MDM,
PJC, and KG contributed to the data analysis. CPH, STW, EKS, PJC provided domain expertise
for the analysis and interpretation of the results. EM was the lead author of the manuscript. All
authors contributed to writing and revising the manuscript.

# **8** Competing interests

JHY received consulting fees from Bridge BioTherapeutics. PJC received consulting fees from Verona
Pharmaceuticals and research support from Bayer and Sanofi, both outside of this work. In the past
three years, EKS received grant support from Bayer and Northpond Laboratories. STW receives
royalties from UpToDate and is on the Board of Histolix, a digital pathology company.

# **560** 9 Acknowledgments

This work was supported by grants from the NHLBI (EM: K01HL166705; MDM: K25HL168157; STW:
PO1HL132825; KG: R01HL155749). The COPDGene study (NCT00608764) is supported by grants
from the NHLBI (U01HL089897 and U01HL089856) and by NIH contract 75N92023D00011 and by
the COPD Foundation through contributions made to an Industry Advisory Committee that has
included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline,
Novartis, Pfizer and Sunovion.